<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Soleno Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/soleno-therapeutics-inc</link>
<description>Latest news and press releases for Soleno Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 06 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/soleno-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c06b78dffbe2df1187c1.webp</url>
<title>Soleno Therapeutics, Inc.</title>
<link>https://6ix.com/company/soleno-therapeutics-inc</link>
</image>
<item>
<title>Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/neurocrine-to-acquire-soleno-therapeutics-expanding-its-endocrinology-and-rare-disease-portfolio-1</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/neurocrine-to-acquire-soleno-therapeutics-expanding-its-endocrinology-and-rare-disease-portfolio-1</guid>
<pubDate>Mon, 06 Apr 2026 11:00:00 GMT</pubDate>
<description>Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Soleno Therapeutics, Inc. (Nasdaq: SLNO) today announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion.</description>
</item>
<item>
<title>Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-retirement-of-james-mackaness-and-appointment-of-jennifer-fulk-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-retirement-of-james-mackaness-and-appointment-of-jennifer-fulk-as-chief-financial-officer</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-update-on-us-launch-of-vykattm-xr</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-update-on-us-launch-of-vykattm-xr</guid>
<pubDate>Wed, 25 Feb 2026 21:01:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT X</description>
</item>
<item>
<title>Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-report-fourth-quarter-130000771</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-report-fourth-quarter-130000771</guid>
<pubDate>Wed, 11 Feb 2026 13:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its fourth quarter and full-year 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, February 25, 2026. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the</description>
</item>
<item>
<title>Soleno Therapeutics to Participate in Upcoming Conferences</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-participate-upcoming-conferences-2026-01-29</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-participate-upcoming-conferences-2026-01-29</guid>
<pubDate>Thu, 29 Jan 2026 05:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-select-preliminary-fourth-quarter-and-full-year-2025</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-select-preliminary-fourth-quarter-and-full-year-2025</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-publication-results-pivotal-study-vykattm-xr-journal</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-publication-results-pivotal-study-vykattm-xr-journal</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics Announces the Passing of Board Member William G. Harris</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-passing-board-member-william-g-harris-2025-12-03</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-passing-board-member-william-g-harris-2025-12-03</guid>
<pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-present-piper-sandler-37th-annual-healthcare-conference-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-present-piper-sandler-37th-annual-healthcare-conference-2025-11</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-entry-100-million-accelerated-share-repurchase</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-entry-100-million-accelerated-share-repurchase</guid>
<pubDate>Tue, 11 Nov 2025 05:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-reports-third-quarter-2025-financial-results-and-provides-update</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-reports-third-quarter-2025-financial-results-and-provides-update</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics to Participate in Upcoming November Conferences</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-participate-upcoming-november-conferences-2025-10-28</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-participate-upcoming-november-conferences-2025-10-28</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-report-third-quarter-2025-financial-results-november-4-2025-4-30</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-report-third-quarter-2025-financial-results-november-4-2025-4-30</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-appoints-biopharmaceutical-executive-mark-w-hahn-its-board</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-appoints-biopharmaceutical-executive-mark-w-hahn-its-board</guid>
<pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
<description>Appointment adds three decades of financial and operational leadership to Soleno’s Board REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno</description>
</item>
<item>
<title>Soleno Therapeutics to Participate in Upcoming September Conferences</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-participate-upcoming-september-conferences-2025-08-27</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-participate-upcoming-september-conferences-2025-08-27</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-provides-update-us-launch-vykattm-xr-and-reports-second-quarter</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-provides-update-us-launch-vykattm-xr-and-reports-second-quarter</guid>
<pubDate>Wed, 06 Aug 2025 04:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-report-second-quarter-2025-financial-results-august-6-2025-4-30</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-report-second-quarter-2025-financial-results-august-6-2025-4-30</guid>
<pubDate>Mon, 28 Jul 2025 04:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-pricing-200-million-public-offering-common-stock-2025</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-pricing-200-million-public-offering-common-stock-2025</guid>
<pubDate>Thu, 10 Jul 2025 04:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-proposed-200-million-public-offering-common-stock-2025</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-proposed-200-million-public-offering-common-stock-2025</guid>
<pubDate>Thu, 10 Jul 2025 04:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel</description>
</item>
<item>
<title>Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025</title>
<link>https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-preliminary-financial-and-operational-results-second</link>
<guid isPermaLink="true">https://6ix.com/company/soleno-therapeutics-inc/news/soleno-therapeutics-announces-preliminary-financial-and-operational-results-second</guid>
<pubDate>Thu, 10 Jul 2025 04:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel</description>
</item>
</channel>
</rss>